Hepatic Veno-Occlusive Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HPT046 MIFTS: 55	Hepatic Veno-Occlusive Disease Categories: Cardiovascular diseases, Gastrointestinal diseases, Liver diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hepatic Veno-Occlusive Disease

MalaCards integrated aliases for Hepatic Veno-Occlusive Disease:

Name: Hepatic Veno-Occlusive Disease ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁵³ ⁴³ ¹⁴ ⁷¹ ³¹ ³³

Sinusoidal Obstruction Syndrome ¹⁹ ⁵⁸

Veno-Occlusive Disease ¹¹ ⁵³

Veno-Occlusive Disease of the Liver ³³

Hepatic Venoocclusive Disease ⁷⁵

Hepatic Vein Thrombosis ⁷¹

Hepatic Vein Occlusion ⁷¹

Venoocclusive Disease ⁷¹

Budd-Chiari Syndrome ⁷¹

Characteristics:

Age Of Onset:

All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases Liver diseases Cardiovascular diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the digestive system

Diseases of liver

Other diseases of liver

Hepatic veno-occlusive disease

ICD11: ³³

Diseases of the digestive system

Diseases of liver

Vascular disorders of the liver

Hepatic veno-occlusive disease

Orphanet: ⁵⁸

Rare hepatic diseases

External Ids:

Disease Ontology ¹¹ DOID:0080177

MeSH ⁴³ D006504

ICD10 ³¹ K76.5

MESH via Orphanet ⁴⁴ D006504

ICD10 via Orphanet ³² K76.5

UMLS via Orphanet ⁷² C0019156

Orphanet ⁵⁸ ORPHA890

SNOMED-CT via HPO ⁶⁹ 13920009 161831008 166603001 more

ICD11 ³³ 762044088

UMLS ⁷¹ C0019154 C0019156 C0856761 more

Sources

Summaries for Hepatic Veno-Occlusive Disease

GARD: ¹⁹ A disorder characterized by damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is usually the side effect of high dose chemotherapy in preparation for stem cell transplantation. Less frequently it may be caused by ingestion of plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention.

MalaCards based summary: Hepatic Veno-Occlusive Disease, also known as sinusoidal obstruction syndrome, is related to pulmonary edema and budd-chiari syndrome. An important gene associated with Hepatic Veno-Occlusive Disease is SERPINC1 (Serpin Family C Member 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Signaling by Receptor Tyrosine Kinases. The drugs Inotuzumab ozogamicin and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and endothelial, and related phenotypes are hepatomegaly and renal insufficiency

Orphanet: ⁵⁸ A rare vascular liver disease characterized by toxic injury to the hepatic sinusoidal capillaries that leads to obstruction of the small hepatic veins and sinusoids. Clinical manifestations include painful hepatomegaly, jaundice, and fluid retention that manifests by weight gain, edemas, and ascites.

Disease Ontology: ¹¹ A hepatic vascular disease that is characterized by obstruction of some of the small veins of the liver.

Wikipedia: ⁷⁵ Hepatic veno-occlusive disease (VOD) or veno-occlusive disease with immunodeficiency is a potentially... more...

Sources

Related Diseases for Hepatic Veno-Occlusive Disease

Diseases related to Hepatic Veno-Occlusive Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)

#	Related Disease	Score	Top Affiliating Genes
1	pulmonary edema	31.3	SERPINC1 CXCL8 CSF3
2	budd-chiari syndrome	31.1	SERPINC1 PLG F3
3	pulmonary hypertension	31.1	VEGFA THBD SULT1A3 SERPINE1 FGF2 F3
4	hepatic coma	30.8	SERPINC1 F3
5	factor viii deficiency	30.7	SERPINC1 F8 F3
6	esophageal varix	30.7	THPO SERPINC1 F3
7	vitamin k deficiency bleeding	30.5	SERPINC1 F8 F3
8	mucositis	30.5	VEGFA CSF3 ABCB1
9	protein c deficiency	30.4	THBD SERPINE1 SERPINC1
10	antithrombin iii deficiency	30.4	SERPINC1 PLG F3
11	thrombophilia due to thrombin defect	30.4	THBD SERPINE1 SERPINC1 PLAT F8 F3
12	liver cirrhosis	30.4	THPO SLC17A5 SERPINC1 HFE F3
13	viral hepatitis	30.3	THPO THBD SLC17A5 HFE
14	varicose veins	30.3	VEGFA THBD SERPINC1 PLAT HFE CXCL8
15	toxic shock syndrome	30.3	SERPINC1 F3 CXCL8 CSF3
16	endocarditis	30.3	SERPINE1 SERPINC1 PLAT CXCL8
17	hemolytic uremic syndrome, atypical 1	30.3	THBD PLG F3
18	disseminated intravascular coagulation	30.3	THBD SERPINE1 SERPINC1 PLG PLAT F3
19	thrombotic thrombocytopenic purpura	30.3	THBD SERPINE1 SERPINC1 F8 F3
20	polycythemia	30.3	VEGFA THPO F3
21	hemophagocytic lymphohistiocytosis	30.3	F3 CXCL8 CSF3
22	nonbacterial thrombotic endocarditis	30.3	SERPINC1 PLG PLAT F3
23	bilirubin metabolic disorder	30.3	VEGFA SLC17A5 SERPINC1 F3 CXCL8 CSF3
24	mitral valve stenosis	30.2	SERPINC1 PLG PLAT F3
25	pericarditis	30.2	SLC17A5 CXCL8 AZU1
26	portal vein thrombosis	30.2	THPO THBD SERPINC1 PLG F8 F3
27	cardiac tamponade	30.2	PLG PLAT F8 F3
28	atrial heart septal defect	30.2	SERPINC1 PLG PLAT F3
29	purpura	30.2	THPO THBD SERPINC1 F3 CXCL8
30	exanthem	30.2	VEGFA F3 CXCL8 CSF3
31	arteriovenous malformation	30.2	VEGFA PLG PLAT F3
32	myeloproliferative neoplasm	30.2	THPO THBD FGF2 CSF3
33	patent ductus arteriosus 1	30.1	VEGFA F3 CXCL8
34	compartment syndrome	30.1	SERPINC1 PLG F8 F3
35	kidney disease	30.1	VEGFA THBD SERPINE1 HFE FGF2 CXCL8
36	behcet syndrome	30.1	VEGFA THBD SERPINC1 F3 CXCL8 CSF3
37	hemolytic-uremic syndrome	30.1	THBD SERPINE1 SERPINC1 PLG F3 CXCL8
38	sickle cell anemia	30.1	SERPINC1 F3 CSF3
39	hypersplenism	30.1	THPO SERPINC1 F3 CSF3
40	leukemia, acute lymphoblastic	30.0	TPMT THPO SERPINC1 CSF3 CD33 ABCB1
41	thrombosis	30.0	THBD SERPINE1 SERPINC1 PLG PLAT F8
42	vascular disease	30.0	VEGFA THBD SERPINE1 SERPINC1 PLAT FGF2
43	pancytopenia	30.0	TPMT THPO CSF3 CD33
44	poems syndrome	30.0	VEGFA FGF2 CXCL8 CSF3
45	thrombophlebitis	29.9	SERPINE1 SERPINC1 PLG PLAT F8 F3
46	acute leukemia	29.9	TPMT THPO CSF3 ABCB1
47	neutropenia	29.9	TPMT THPO CXCL8 CSF3 ABCB1
48	leukemia, chronic myeloid	29.9	VEGFA THPO CSF3 CD33 ABCB1
49	aspergillosis	29.9	PLG CXCL8 CSF3
50	leukemia, acute myeloid	29.9	VEGFA THPO FGF2 CXCL8 CSF3 CD33

Comorbidity relations with Hepatic Veno-Occlusive Disease via Phenotypic Disease Network (PDN):

Heart Disease

Graphical network of the top 20 diseases related to Hepatic Veno-Occlusive Disease:

Sources

Symptoms & Phenotypes for Hepatic Veno-Occlusive Disease

Human phenotypes related to Hepatic Veno-Occlusive Disease:

⁵⁸ ³⁰ (show all 12)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	hepatomegaly ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002240
2	renal insufficiency ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000083
3	ascites ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001541
4	elevated hepatic transaminase ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002910
5	jaundice ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000952
6	abdominal pain ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002027
7	respiratory failure ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002878
8	increased total bilirubin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003573
9	increased body weight ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0004324
10	prolonged partial thromboplastin time ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003645
11	hepatic encephalopathy ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002480
12	abnormality of coagulation ⁵⁸		Frequent (79-30%)

GenomeRNAi Phenotypes related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.17	ABCB1 AZU1 CD33 CSF3 CXCL8 F3
2	no effect	GR00402-S-2	10.17	CSF3 F3 F8 FGF2 HFE PLAT

MGI Mouse Phenotypes related to Hepatic Veno-Occlusive Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.06	ABCB1 CD33 F3 F8 FGF2 HFE
2	liver/biliary system	MP:0005370	9.86	ABCB1 HFE PLG SERPINC1 SERPINE1 SULT1A3
3	immune system	MP:0005387	9.8	ABCB1 CD33 CSF3 F3 F8 HFE
4	hematopoietic system	MP:0005397	9.5	ABCB1 CD33 CSF3 F3 F8 FGF2

Sources

Drugs & Therapeutics for Hepatic Veno-Occlusive Disease

Drugs for Hepatic Veno-Occlusive Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Inotuzumab ozogamicin

Approved, Investigational

Phase 4

635715-01-4

Anti-Bacterial Agents

Phase 4

Antineoplastic Agents, Immunological

Phase 4

Immunoglobulins

Phase 4

Antibodies

Phase 4

Antibiotics, Antitubercular

Phase 4

Defibrotide

Approved, Investigational

Phase 3

83712-60-1

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 3

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 3

9041-08-1

Alprostadil

Approved, Investigational

Phase 2, Phase 3

745-65-3

5280723

Anticoagulants

Phase 3

Fibrinolytic Agents

Phase 3

Platelet Aggregation Inhibitors

Phase 3

Anti-Inflammatory Agents

Phase 3

Coagulants

Phase 3

Heparin, Low-Molecular-Weight

Phase 3

Calcium heparin

Phase 3

Cola

Phase 3

bilirubin

Phase 2, Phase 3

635-65-4

5280352

Orange

Approved

Phase 1, Phase 2

Acetylcysteine

Approved, Investigational

Phase 2

616-91-1

581 12035

Imatinib Mesylate

Phase 1, Phase 2

220127-57-1

Protein Kinase Inhibitors

Phase 1, Phase 2

HIV Protease Inhibitors

Phase 2

Serine Proteinase Inhibitors

Phase 2

Antithrombins

Phase 2

Antithrombin III

Phase 2

protease inhibitors

Phase 2

Antiviral Agents

Phase 2

Anti-Infective Agents

Phase 2

Expectorants

Phase 2

Antidotes

Phase 2

Pharmaceutical Solutions

Phase 2

N-monoacetylcystine

Phase 2

Respiratory System Agents

Phase 2

Antioxidants

Phase 2

Protective Agents

Phase 2

Serine

Investigational, Nutraceutical

Phase 2

56-45-1

5951

Oxaliplatin

Approved, Investigational

61825-94-3

43805 11947679 6857599

Bevacizumab

Approved, Investigational

216974-75-3

135329020

Protein C

Approved

Atezolizumab

Approved, Investigational

1380723-44-3

L-Glutamine

Approved, Investigational, Nutraceutical

56-85-9

5961

Antimitotic Agents

Angiogenesis Inhibitors

Factor VIII

Protein S

Antibodies, Monoclonal

Immunologic Factors

Interventional clinical trials:

(show all 35)

#	Name	Status	NCT ID	Phase	Drugs
1	Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome	Active, not recruiting	NCT03858530	Phase 4
2	A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE	Active, not recruiting	NCT03677596	Phase 4	inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
3	Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients	Withdrawn	NCT03963999	Phase 4	Contrast Enhanced Ultrasound (CEUS)
4	Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study	Completed	NCT00628498	Phase 3	Defibrotide
5	Prospective Randomized Study of the Incidence and Outcome of Veno-Occlusive Disease (VOD) With the Prophylactic Use of Defibrotide (DF) in Pediatric Stem Cell Transplantation	Completed	NCT00272948	Phase 2, Phase 3	Defibrotide
6	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy	Completed	NCT00358501	Phase 3	Defibrotide
7	A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant	Completed	NCT02851407	Phase 3	Defibrotide
8	A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters	Completed	NCT00006083	Phase 3	Fragmin
9	Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer	Completed	NCT00003674	Phase 3	dalteparin;standard therapy
10	Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT	Active, not recruiting	NCT02338440	Phase 2, Phase 3	lipoprostaglandin E1
11	Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose	Completed	NCT00003966	Phase 2	defibrotide
12	Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis	Completed	NCT00891527	Phase 1, Phase 2	Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
13	Phase II Open Label Study to Assess Efficacy of 5-day Defibrotide Treatment for Hepatic SOS/VOD	Recruiting	NCT04313036	Phase 2	Defibrotide
14	Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation	Active, not recruiting	NCT01886248	Phase 2	Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
15	Prospective, Randomized Study Using N-Acetylcysteine as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation	Not yet recruiting	NCT04712435	Phase 2	N-acetylcysteine;Placebo
16	Hepatic Artery Infusion of CD34+ Cells, Isolated by the Isolex 300i Device, in Stem Cell Transplant Recipients With Hepatic Failure Due to Veno-occlusive Disease	Withdrawn	NCT00062543	Phase 1
17	Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic Veno-occlusive Disease in Children With Nephroblastoma or Acute Lymphoblastic Leukemia	Unknown status	NCT04168788
18	A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.	Unknown status	NCT00563498		Glutamine
19	A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®	Completed	NCT03032016
20	A Retrospective Study About Detection of Sinusoidal Obstruction Syndrome With Ultrasound After Allogeneic Hematopoietic Stem Cell Transplantation	Completed	NCT04141735
21	Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome	Completed	NCT02483481
22	Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study	Completed	NCT03426358
23	Prevention of the Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-based Neoadjuvant Chemotherapy for Colorectal Liver Metastases by Means of Anticoagulants	Completed	NCT00885950
24	Pharmacogenetics of Veno-Occlusive Disease (VOD) in Children With Haematological Stem Cell Transplantation (HSCT)	Completed	NCT03664427
25	To Compare "Balloon Occluded Thrombolysis" With "Conventional Catheter Directed Thrombolysis" in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome.	Completed	NCT05117684
26	Balloon Angioplasty Alone Versus in Combination With Stent Placement for the Treatment of Budd-Chiari Syndrome in China: An Randomized Controlled Trial	Completed	NCT02201485
27	Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome	Recruiting	NCT03865589
28	A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).	Recruiting	NCT05090345
29	Prospective Evaluation of Coagulation Status and Thromboelastometry Guided Management of Genetic and Acquired Thrombophilia in Patients With Portal Vein Thrombosis and Budd-Chiari Syndrome	Recruiting	NCT05123326
30	Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank	Recruiting	NCT03541057
31	A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Tumor Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment	Recruiting	NCT04649489		Atezolizumab
32	Biomarkers of Endothelial Dysfunction in Pediatric Patients Receiving High Intensity Chemotherapy/Irradiation	Active, not recruiting	NCT03132337
33	Compassionate Use of Defibrotide for Patients With Veno-Occlusive Disease	No longer available	NCT00143546		Defibrotide
34	Defibrotide Compassionate Use Protocol for Patients With Life Threatening Veno-Occlusive Disease of the Liver	No longer available	NCT00263978		Defibrotide
35	Portal Vein Thrombosis in Cirrhosis: A Cohort Sudy	Withdrawn	NCT02275585

Search NIH Clinical Center for Hepatic Veno-Occlusive Disease

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Antithrombin III, Human

ANTITHROMBIN III,RECOMBINANT

Cochrane evidence based reviews: hepatic veno-occlusive disease

Sources

Genetic Tests for Hepatic Veno-Occlusive Disease

Sources

Anatomical Context for Hepatic Veno-Occlusive Disease

Organs/tissues related to Hepatic Veno-Occlusive Disease:

MalaCards : Liver, Bone Marrow, Endothelial, Bone, Myeloid, Lung, Kidney

Sources

Publications for Hepatic Veno-Occlusive Disease

Articles related to Hepatic Veno-Occlusive Disease:

(show top 50) (show all 2941)

#	Title	Authors	PMID	Year
1	The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. ⁵³ ⁶²	Lennard L...UK MRC/NCRI Childhood Leukaemia Working Party	17015055	2006
2	Costs of allogeneic hematopoietic stem cell transplantation. ⁵³ ⁶²	Svahn BM...Remberger M	16858272	2006
3	Control of hepatic veno-occlusive disease with an antithrombin-III concentrate-based therapy. ⁵³ ⁶²	Shin-Nakai N...Imashuku S	16490079	2006
4	Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. ⁵³ ⁶²	Ibrahim RB...Klein J	15113990	2004
5	Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). ⁵³ ⁶²	Kaleelrahman M...Chopra R	12745658	2003
6	Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. ⁵³ ⁶²	Lee JH...Lee JS	12199790	2002
7	Multiple organ dysfunction syndrome in hematopoietic stem cell transplantation. ⁵³ ⁶²	Haire WD	12004245	2002
8	Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome. ⁵³ ⁶²	Kikuchi K...McDonald GB	11896430	2002
9	Growth factors and hemostasis: differential effects of GM-CSF and G-CSF on coagulation activation--laboratory and clinical evidence. ⁵³ ⁶²	Bonig H...Nurnberger W	11669301	2001
10	Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. ⁵³ ⁶²	Mertens R...Nowak-Gottl U	10650858	1999
11	Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. ⁵³ ⁶²	Schriber J...Herzig G	10627640	1999
12	The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. ⁵³ ⁶²	Salat C...Hiller E	10194118	1999
13	Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. ⁵³ ⁶²	Lee JH...Kim SH	9827816	1998
14	Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. ⁵³ ⁶²	Nurnberger W...Gobel U	9540759	1998
15	Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. ⁵³ ⁶²	Salat C...Hiller E	9058743	1997
16	Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation. ⁵³ ⁶²	Salat C...Hiller E	9052916	1997
17	Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease. ⁵³ ⁶²	Salat C...Hiller E	9438165	1996
18	Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. ⁵³ ⁶²	Leahey AM...Bunin NJ	8807121	1996
19	Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team. ⁵³ ⁶²	Kanda Y...Onozawa Y	8602625	1996
20	Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. ⁵³ ⁶²	Patton DF...Haire WD	8704704	1996
21	Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis. ⁵³ ⁶²	Simpson DR...Palmer SJ	7858540	1994
22	Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. ⁵³ ⁶²	Ringden O...Groth CG	1354293	1992
23	Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation. ⁵³ ⁶²	Rosti G...Miggiano C	1351153	1992
24	Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation. ⁵³ ⁶²	Laporte JP...Gorin NC	1349081	1992
25	Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. ⁶²	McCall D...Cuglievan B	36031729	2023
26	Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin. ⁶²	Iwai T...Teshima T	36308679	2022
27	Retrorsine Cooperates with Gut Microbiota to Promote Hepatic Sinusoidal Obstruction Syndrome by Disrupting the Gut Barrier. ⁶²	Xiao L...Yang L	36381109	2022
28	Effects of bicyclol on hepatic sinusoidal obstruction syndrome induced by Gynura segetum. ⁶²	Yao J...Yao X	36447383	2022
29	Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression. ⁶²	Xiang H...Song Y	36354295	2022
30	Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome. ⁶²	Zhu C...Zhang C	36177905	2022
31	Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors. ⁶²	Velev M...Michot JM	36473326	2022
32	Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome. ⁶²	Saito R...Sakamoto N	36042137	2022
33	Hepatic venous pressure gradient in sinusoidal obstruction syndrome: diagnostic value and link with histological lesions. ⁶²	Gressens SB...Rautou PE	36160755	2022
34	In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed. ⁶²	Bonanini F...Vulto P	35704148	2022
35	Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study. ⁶²	Chalandon Y...Masouridi-Levrat S	35953029	2022
36	Hematopoietic stem cell transplantation in serine/threonine kinase 4 (STK4) deficiency: Report of two cases and literature review. ⁶²	Uygun V...Yesilipek A	36394186	2022
37	Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma. ⁶²	Fried S...Shimoni A	36343892	2022
38	Higher Cryopreserved CD34+ Cell Dose Is Associated with Decreased Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Single-Unit Cord Blood Transplantation in Adults Given Prophylactic Ursodeoxycholic Acid and Intravenous Heparin. ⁶²	Kato S...Nannya Y	35995391	2022
39	A stitch in time saves nine: timely use of N-acetyl cysteine (NAC) for chemotherapy-induced veno-occlusive disease (VOD)-is it a cost-effective alternative? ⁶²	Tandra HV...T PK	35963952	2022
40	Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. ⁶²	Triantafyllidi H...Iliodromitis E	35905554	2022
41	Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease. ⁶²	Ma B...Zhou Z	36400028	2022
42	Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developing during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report. ⁶²	Mouri M...Mori M	36416547	2022
43	A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease. ⁶²	Zhang C...Zhang R	36451176	2022
44	A case of glucocorticoid-resistant adult Still's disease complicated by pulmonary hypertension and interstitial lung disease. ⁶²	Kusaka K...Tanaka Y	36250713	2022
45	A case of percutaneous transhepatic stomal varices embolization and partial splenic artery embolization for rectal cancer after CAPOX/BEV chemotherapy: the summary of the stomal varices related to oxaliplatin administration. ⁶²	Mizukami S...Sumi Y	36266604	2022
46	Plugged percutaneous liver biopsy using Tru-cut needle and coils: A retrospective study. ⁶²	Rathod K...Bhatia S	36422847	2022
47	Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore). ⁶²	Bris PN...Bisbal M	35968907	2022
48	Hematopoietic Stem Cell Transplantation in ARPC1B Deficiency. ⁶²	Giardino S...Faraci M	35767111	2022
49	A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). ⁶²	Nakayama H...Horibe K	35635686	2022
50	[Risk factors for acute kidney injury after hematopoietic stem cell transplantation in children: a retrospective study]. ⁶²	Liu J...Liu YF	36305115	2022

Sources

Genes for Hepatic Veno-Occlusive Disease

Genes related to Hepatic Veno-Occlusive Disease (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	SERPINC1	Serpin Family C Member 1	Protein Coding	27.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12004245 16490079 9827816 (more) 10650858 8704704 9438165 11896430 15113990
2	SERPINE1	Serpin Family E Member 1	Protein Coding	26.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9540759 9058743 10194118 (more) 12745658 12199790 9052916
3	PLAT	Plasminogen Activator, Tissue Type	Protein Coding	26.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1351153 1354293 1349081 (more) 8807121 7858540 10627640
4	THBD	Thrombomodulin	Protein Coding	19.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9540759
5	PLG	Plasminogen	Protein Coding	14.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	SP110	SP110 Nuclear Body Protein	Protein Coding	14.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	F3	Coagulation Factor III, Tissue Factor	Protein Coding	14.27	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	CSF3	Colony Stimulating Factor 3	Protein Coding	13.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16858272 8602625 11669301
9	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	13.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	12.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	THPO	Thrombopoietin	Protein Coding	12.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	HFE	Homeostatic Iron Regulator	Protein Coding	12.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	F8	Coagulation Factor VIII	Protein Coding	12.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	12.01	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	FGF2	Fibroblast Growth Factor 2	Protein Coding	11.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	TPMT	Thiopurine S-Methyltransferase	Protein Coding	9.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17015055
17	SULT1A3	Sulfotransferase Family 1A Member 3	Protein Coding	9.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9540759
18	SLC17A5	Solute Carrier Family 17 Member 5	Protein Coding	8.62	GeneCards inferred via : Publications (show sections)
19	AZU1	Azurocidin 1	Protein Coding	8.21	GeneCards inferred via : Publications (show sections)
20	CD33	CD33 Molecule	Protein Coding	7.58	DISEASES inferred ¹⁴
21	CD22	CD22 Molecule	Protein Coding	7.06	DISEASES inferred ¹⁴
22	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	6.88	DISEASES inferred ¹⁴ ¹⁴
23	CD34	CD34 Molecule	Protein Coding	6.7	DISEASES inferred ¹⁴

Sources

Variations for Hepatic Veno-Occlusive Disease

Sources

Expression for Hepatic Veno-Occlusive Disease

Search GEO for disease gene expression data for Hepatic Veno-Occlusive Disease.

Sources

Pathways for Hepatic Veno-Occlusive Disease

Pathways related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

(show all 14)

#	Super pathways	Score	Top Affiliating Genes
1	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	12.67	VEGFA THPO THBD SERPINE1 SERPINC1 PLG
2	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.57	VEGFA PLG PLAT FGF2 F3
3	Gastrin signaling pathway ⁷⁴	11.76	VEGFA SERPINE1 CXCL8
4	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.73	VEGFA FGF2 CXCL8
5	Senescence and autophagy in cancer ⁷⁴	11.71	SERPINE1 PLAT CXCL8
6	CCL18 signaling pathway ⁷⁴	11.65	VEGFA FGF2 CXCL8
7	Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) ⁶⁶ Show member pathways Blood clotting cascade ⁷⁴ Blood Coagulation Signaling Pathways ⁶⁵ Common Pathway of Fibrin Clot Formation ⁶⁶ Complement and coagulation cascades ⁷⁴ Defective F8 binding to von Willebrand factor ⁶⁶ Defective F8 cleavage by thrombin ⁶⁶ Defective F8 sulfation at Y1699 ⁶⁶ Defective F9 activation ⁶⁶ Defective F9 secretion ⁶⁶ Defective factor IX causes hemophilia B ⁶⁶ Defective factor VIII causes hemophilia A ⁶⁶ Defective factor XII causes hereditary angioedema ⁶⁶ Defective gamma-carboxylation of F9 ⁶⁶ Diseases of hemostasis ⁶⁶ Extrinsic Pathway of Fibrin Clot Formation ⁶⁶ Extrinsic Prothrombin Activation Pathway ⁶⁴ Formation of Fibrin Clot (Clotting Cascade) ⁶⁶ Intrinsic Pathway of Fibrin Clot Formation ⁶⁶ Thrombin/protease-activated receptor (PAR) pathway ⁶¹	11.63	THBD SERPINE1 SERPINC1 PLG PLAT F8
8	Allograft rejection ⁷⁴	11.62	VEGFA CXCL8 ABCB1
9	HIF-1-alpha transcription factor network ⁶¹	11.42	VEGFA SERPINE1 ABCB1
10	Lung fibrosis ⁷⁴	11.38	FGF2 CXCL8 CSF3
11	Cell adhesion_ECM remodeling ²²	11.34	SERPINE1 PLG PLAT CXCL8
12	Cell adhesion_Plasmin signaling ²²	11.15	VEGFA PLG PLAT FGF2
13	Glypican 1 network ⁶¹	10.82	FGF2 SERPINC1 VEGFA
14	Dissolution of Fibrin Clot ⁶⁶	10.61	SERPINE1 PLG PLAT

Sources

GO Terms for Hepatic Veno-Occlusive Disease

Cellular components related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.22	VEGFA THPO SERPINE1 SERPINC1 PLG PLAT
2	extracellular space	GO:0005615	9.77	VEGFA THPO THBD SERPINE1 SERPINC1 PLG
3	serine protease inhibitor complex	GO:0097180	9.56	SERPINE1 PLAT
4	platelet alpha granule lumen	GO:0031093	9.56	F8 PLG SERPINE1 VEGFA

Biological processes related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.26	VEGFA HFE FGF2 F3 CXCL8 AZU1
2	positive regulation of angiogenesis	GO:0045766	10.07	VEGFA SERPINE1 FGF2 F3 CXCL8
3	positive regulation of protein kinase B signaling	GO:0051897	9.91	VEGFA THPO FGF2 F3 CSF3
4	fibrinolysis	GO:0042730	9.88	SERPINE1 PLG PLAT
5	negative regulation of plasminogen activation	GO:0010757	9.8	SERPINE1 PLAT
6	induction of positive chemotaxis	GO:0050930	9.8	AZU1 CXCL8 VEGFA
7	negative regulation of fibrinolysis	GO:0051918	9.76	THBD SERPINE1 PLG PLAT
8	trans-synaptic signaling by BDNF, modulating synaptic transmission	GO:0099183	9.73	PLAT PLG
9	blood coagulation	GO:0007596	9.73	THBD SERPINC1 PLG PLAT F8 F3
10	positive regulation of epithelial tube formation	GO:1905278	9.63	VEGFA FGF2
11	hemostasis	GO:0007599	9.02	THBD SERPINC1 PLG F8 F3

Molecular functions related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.9	THPO SERPINE1 PLG PLAT HFE CSF3
2	cytokine activity	GO:0005125	9.61	VEGFA THPO FGF2 CXCL8 CSF3
3	heparin binding	GO:0008201	9.32	VEGFA SERPINC1 FGF2 CXCL8 AZU1